SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The ...

SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Comp ...

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SQFT; SQFTP; SQFTW) Presidio Property Trust, Inc. (“Presidio” or the “Company”), an internally managed, diversified real estate investment trust, announced today that it will proceed with a 1-for-10 reverse stock split (“Reverse Stock Split”) of its outstanding shares of Series A Common Stock following approval by its Board of Directors pursuant to the Maryland General Corporation Law and no stockholder approval is required. Presidio expects the Company’s ...

Vaxart (VXRT) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Edward Berg - Senior Vice President and General CounselSteven Lo - CEO , President & DirectorJames Cummings - Chief Medical OfficerSean Tucker - Founder & Chief Scientific OfficerPhillip Lee - Chief Financial OfficerCheng Li - Director - Equity ResearchMayank Mamtani - Senior Managing Director & Group Head of HealthcareLiang Cheng - Senior Research Associate Operator Greetings. Welcome to Vaxart Business Update and First Quart ...

Vaxart (VXRT) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Greetings. Welcome to Vaxart Business Update and First Quarter twenty twenty five Financial Results Conference Call. A question and answer session will follow management's opening remarks. Individual investors may submit written questions to vaxart.com. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel. Speaker1 Good afternoon, and w ...

Core Points - Altisource Portfolio Solutions S.A. announced a reverse stock split approved by shareholders, consolidating every eight shares into one, reducing outstanding shares from approximately 88.95 million to about 11.12 million [1][2] - The reverse stock split is set to take effect on May 28, 2025, following necessary administrative procedures [2] - Shareholders must hold shares in multiples of eight by market close on May 27, 2025, to avoid receiving cash for fractional shares [3][4] - Fractional shares will be redeemed for cash at the closing price on May 27, 2025, and proceeds will be distributed pro rata without interest [3][4] - The consolidation aims to help the company comply with Nasdaq's minimum bid price requirement of $1.00 [5] Share Consolidation Details - The reverse stock split will reduce the total number of outstanding shares significantly, which is a strategic move to enhance the company's stock price [2][5] - The company has filed a definitive proxy statement with the U.S. Securities and Exchange Commission detailing the rationale and effects of the share consolidation [5] Shareholder Actions - Shareholders are encouraged to check with their financial intermediaries to ensure their holdings are in amounts divisible by eight to avoid cash-out for fractional shares [4] - The company will handle fractional shares by redeeming them for cash, ensuring that shareholders are informed of the process [3][4]

Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder questions regarding a reverse stock split proposal at the Company’s Annual Meeting taking place on Wednesday, May 21, 2025, to regain Nasdaq compliance. 1) Why is Vaxart proposing a reverse stock split? a. Vaxart is at risk of being delisted from Nasdaq si ...

PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock split of the Company’s common stock and has determined the ratio to be 1-for-30. The Company’s stockholders approved the reverse stock split and granted the Longevity board of directors the authority to determine the exact split ratio and when to proceed with ...

Core Viewpoint - Stock splits can indicate a company's performance, with forward splits often seen positively, while reverse splits may signal struggles, as exemplified by Tilray Brands [1][2][4]. Group 1: Stock Splits - A forward stock split increases the number of shares for each investor, often indicating expected strong performance and making shares more affordable [2]. - A reverse stock split reduces the number of shares and increases the stock price proportionately, often used to avoid delisting from major exchanges [2][3]. Group 2: Tilray's Performance - Tilray has faced significant challenges, with its share price dropping below $1, currently at approximately $0.43, indicating a long-term downward trend [4]. - The company's financial results are disappointing, with revenue growth largely driven by acquisitions and consistent unprofitability [4][6]. - The legal landscape for cannabis remains difficult, with federal illegality in the U.S. and regulatory barriers in Canada hindering growth [6]. Group 3: Reverse Stock Split Proposal - Tilray announced a special stockholders' meeting to vote on a reverse stock split proposal, which is likely to be approved given the company's current situation [7]. - A reverse stock split would prevent delisting from Nasdaq but does not address the underlying business challenges [8]. Group 4: Future Prospects - Tilray has reduced its focus on cannabis and is now a leading craft brewer in the U.S., hoping for future federal legalization of cannabis [8]. - CEO Irwin Simon anticipates potential legalization during President Trump's second term, which could position Tilray favorably in the cannabis-infused drinks market [9]. - However, uncertainties remain regarding the timeline and specifics of legalization, which could limit market potential [9][10]. Group 5: Investment Outlook - Given the ongoing challenges and lack of attractive business prospects, Tilray is not considered an appealing investment opportunity [10].

BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symb ...